HHS-OIG – Page 20 – Policy & Medicine

Merck Vioxx Corporate Integrity Agreement and Continuing Medical Education Grants

HHS OIG Budget FY 2013 Compliance Assistance and Enforcement

HHS OIG: Pharmaceutical Compliance Roundtable 2012 Report

Government Targeting Pharmaceutical Executives with Renewed Enthusiasm

Healthcare Fraud Prosecution Significantly Increased in First Half of 2011

HHS OIG Releases Work Plan for FY 2012

OIG Complains of HHS Missing Waivers for Potential Conflict of Interest

Judge Dismisses Case Against Former GSK Attorney, Citing “Serious Implications” For the Practice of Law

OIG Seeks to Exclude Forest’s Chief Executive Officer from Working

HHS-OIG: CMS-FDA Drug Registration and Listing Systems In Need of Update